Figure 5From: Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetesPlasma glucagon. When compared to placebo glucagon-like peptide-1 (GLP-1) caused a reduction in glucagon concentration AUC (# P < 0.01) and strong trend to decreased glucagon concentrations at baseline, commencement of feeding and completion of study (P = 0.06, P = 0.06 and P = 0.11 respectively).Back to article page